Why have the Perseus Report experts called for a Covid Vaccine Suspension?

Perseus report questions speed of Covid vaccine licensing in UK. • 1:56

Author, a retired civil servant, raised safety concerns based on experience. • 2:38

Author’s background in Munitions safety management led to questioning vaccine safety. • 5:03

Author found lack of safety audit reports from regulatory agency concerning. • 6:31

Experts raised concerns about the quality audit of vaccine safety management. • 7:00

The Perseus group was formed to address concerns about vaccine licensing and rollout. • 7:53

The speaker initially wrote under a pseudonym due to fear of backlash from pro-vaccine lobbyists. • 9:04

Discussion on the challenges faced by individuals in speaking out against concerns in their current employment. • 9:35

The Perseus report was authored by a team of experts but their names were not disclosed to focus on factual evidence. • 12:23

Experts fear personal attacks if names are attached to report, making it harder to challenge content. • 13:06

Questions raised about expertise of those leading pandemic response after three years of ongoing crisis. • 13:59

Report calls for thorough inquiry into regulatory practices of MHRA and Safety Management of all medicines. • 16:11

Loss of faith in safety of all medicines due to perceived shortcomings in regulatory agencies. • 16:37

Switzerland stops recommending Covid vaccines, opting for individual doctor prescriptions at patient’s cost. • 18:27

Different countries have varying approaches to Covid-19 vaccine safety based on risk perceptions. • 19:06

Scandinavian regulators were quicker to suspend AstraZeneca vaccine compared to UK MHRA. • 19:51

Alarming number of adverse events reported for Covid-19 vaccines compared to other common vaccines. • 22:56

MHRA lacks a formal process for investigating adverse events reported through yellow card system. • 23:12

MHRA’s reluctance to investigate yellow card reports linked to fatalities raises concerns. • 24:23

Lack of transparency and thorough investigation process by MHRA regarding adverse events from Covid-19 vaccines. • 25:07

MHRA claimed it would be costly to investigate yellow cards linked to fatalities from Covid-19 vaccines. • 25:15

Excess deaths patterns overlooked amidst vaccine rollout acceptance. • 25:32

Majority of MHRA funding from pharmaceutical industry. • 25:56

Funding sources for regulation in defense sector differ from pharmaceutical industry. • 26:14

Freedom of Information Act allows questioning of official bodies for information. • 28:03

MHRA approval of Covid vaccine ingredients with limited track record questioned. • 30:34

Authorization of Covid vaccine for pregnant population lacking data unprecedented. • 31:02

Long-term safety data for Covid vaccines is lacking after nine months, raising doubts on accuracy. • 31:17

MHRA lacks proper safety management structure and accountability, with split responsibilities for licensing and monitoring. • 33:16

Absence of individual accountability within MHRA decision-making process raises concerns about safety and effectiveness of medicines. • 34:09

Circumstantial evidence suggests that accountability gaps could lead to delayed recognition of issues with medications. • 36:23

Historical inquiries show significant time lapse between licensing of products and identification of severe limitations or disasters. • 37:05

Experts criticize the decision to vaccinate lower age groups despite limited data on Covid risk. • 37:40

Analogy drawn to military operations where emergency use of munitions requires strict limitations and responsibility. • 38:18

Concerns raised about the lack of rigorous testing before widespread vaccine rollout. • 39:05

Targeted vaccination based on age, comorbidities, and risk was recommended over mass vaccination. • 41:08

Military analogy of soldiers on the ground making urgent decisions in the line of fire. • 43:03

Limited safety evidence for emergency use authorization in military operations. • 43:25

Importance of additional surveillance methods for accurate vaccine-related death data. • 47:19

Culture of not linking Covid vaccine to deaths complicating certification process. • 47:41

Need for Big Data analysis to address circular logic in vaccine-related death assessment. • 48:03

Experts raise concerns about lack of transparency and follow-through by regulatory bodies. • 49:19

Slow response to requests and exemptions applied by regulatory bodies. • 50:02

Personal frustration over delayed responses to inquiries. • 50:39

Call for recognition of harm done to vaccine-injured and bereaved family members. • 51:23

Collaboration with UK parliamentarians and groups to address harm caused by vaccine rollout. • 52:05

Petitions and open letters initiated to demand government action and inquiry into vaccine licensing. • 53:01

Encouragement for individuals globally to ask questions and take action at a local level. • 54:14

National regulators need significant changes to address pharmaceutical industry influenc. • 54:41

Proposed solutions include reorganization, individual product responsibility, safety audits, and cultural chang. • 56:14

General public urged to read the report and pressure leadership for actio. • 57:30

Report sent to UK Parliament members, prompting calls for constituents to engage with their MP. • 57:52

Translation of the report to other languages is challenging due to technical languag. • 59:20

Encouragement for widespread dissemination of the report to drive accountability and actio. • 59:46

Hope for a response from MP on the repor. • 1:00:04

Upcoming Eventbrite presentations on medical explanations for clottin. • 1:00:36

Encouragement to watch out for more programs in the futur. • 1:01:11